As we delve into the realm of Ligand Pharmaceuticals (NASDAQ:LGND) stock, it is evident that over the past 3 months, the insights of 4 analysts have graced our presence. These analysts, hailing from the esteemed Wall Street banks, have dedicated their expertise to comprehending the inner workings of this company, with the ultimate goal of predicting its trajectory in the coming year.
The consensus among these financial savants is that Ligand Pharmaceuticals holds an average price target of $123.25, with a high estimate of $144.00 and a low estimate of $95.00. It is worth noting that this current average has experienced a modest increase of 2.71% from the previous average price target of $120.00.
Now, let us explore the ratings bestowed upon Ligand Pharmaceuticals by these discerning analysts. In the past 3 months, the breakdown is as follows: 3 analysts have expressed a bullish sentiment, 1 analyst leans towards a somewhat bullish stance, while none have displayed any indifference, somewhat bearishness, or outright bearishness towards the stock.
According to the esteemed platform Tipranks, Ligand Pharmaceuticals exhibits a staggering upside potential of 103.09%, based on the average price target provided by the analysts. This remarkable figure has led to a consensus rating of Strong Buy, a testament to the confidence these analysts have in the company’s future prospects.
MarketBeat, on the other hand, paints a slightly different picture. Their analysis reveals that Ligand Pharmaceuticals boasts an average rating score of 3.00, based on 4 buy ratings, no hold ratings, and no sell ratings. These ratings contribute to the analysts’ consensus price target of $112.25, indicating a forecasted upside of 52.2% from the current price of $73.76.
As we immerse ourselves in the realm of Ligand Pharmaceuticals, it becomes apparent that the future holds immense potential for this stock. With the guidance of these astute analysts, investors are presented with a promising opportunity to reap substantial rewards.
Ligand Pharmaceuticals Incorporated
Updated on: 19/09/2023
Debt to equity ratio: Neutral
Price to earnings ratio: Strong Buy
Price to book ratio: Strong Buy
DCF: Strong Buy
5:00 PM (UTC)
Date:19 September, 2023
|Analyst / firm||Rating|
Ligand Pharmaceuticals LGND Stock Shows Stable Performance on September 19, 2023: Positive Earnings Growth Forecast for Long-Term Investors
LGND stock, belonging to the pharmaceutical company Ligand Pharmaceuticals, had a mixed performance on September 19, 2023. The stock opened at $63.11, slightly higher than the previous day’s closing price of $62.56. Throughout the day, its price fluctuated within a range of $62.93 to $63.76. The day’s trading volume was relatively low, with only 2,404 shares being traded.
Ligand Pharmaceuticals has a market capitalization of $1.1 billion, making it a mid-cap company. In terms of earnings growth, the company experienced a significant decline of 157.56% in the previous year. However, it has turned around in the current year, with earnings growth of 75.96%.
The P/E ratio for LGND stock is 27.8, indicating that investors are willing to pay 27.8 times the company’s earnings per share for its stock. The Price/Sales ratio is 5.74, which suggests that investors are valuing the company at 5.74 times its annual revenue. The Price/Book ratio is 1.76, indicating that the stock is trading at 1.76 times its book value.
Ligand Pharmaceuticals is expected to report its next earnings on November 7, 2023. Analysts are forecasting earnings per share of $0.70 for the upcoming quarter.
In the previous year, Ligand Pharmaceuticals generated annual revenue of $196.2 million. However, the company reported a net loss of $33.4 million during that period. This resulted in a net profit margin of -2.66%, indicating that the company’s expenses exceeded its revenue.
Ligand Pharmaceuticals operates in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company is headquartered in San Diego, California.
Overall, LGND stock had a relatively stable performance on September 19, 2023. Despite the negative earnings growth in the previous year, the company has shown improvement in the current year. With a positive earnings growth forecast for the next five years, Ligand Pharmaceuticals may present an attractive investment opportunity for long-term investors.
LGND Stock Analysis: Median Target Price of $103.50 Indicates +63.40% Increase; 6 Analysts Recommend Buying
LGND stock has a median target price of $103.50, representing a +63.40% increase from the last price of $63.34. Six investment analysts recommend buying stock in Ligand Pharmaceuticals Inc. The company reported earnings per share of $0.70 and sales of $28.2 million for the current quarter. The reporting date for these figures is November 7. Investors have confidence in the company’s future performance, but should consider market conditions, industry trends, and company-specific developments. Thorough research and consideration of risk tolerance is advised.